



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2019-20

February 7, 2020

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE ID: AARTIDRUGS
BSE CODE – 524348

To,
Listing/ Compliance Department
**National Stock Exchange of India
Limited,**
“Exchange Plaza”, Bandra - Kurla
Complex, Bandra (E), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Press Release

Press release for December'19

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M.No.: A54527





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Press release for December'19

In the December'19 quarter, the Company recorded consolidated quarterly revenue of Rs.473.51 Crores with year-on-year growth of 24.57%. Domestic sales of the API segment grew by approximately 26.39% and exports by 5.27%. Entire growth of the API segment is driven by volume growth. Formulation segment revenues grew by around 72.50% on year-on-year basis.

Consolidated EBITDA for the quarter ended December'19 is Rs.63.82 Crores, up by 22.68% and consolidated profit after tax for the quarter ended December'19 is Rs.27.78 Crores, up by 33.01% on year-on-year basis. Company expects to improve on its gross margins in recent future due to better efficiencies in production. Due to continuous improvement in working capital management Company was able to further reduce its Debt/Equity ratio to 0.70 as of December'19 on consolidated basis.

Company recently expanded its anti-diabetic capacity and successfully scaled up its production quantities for the same. Further brown field CAPEX is in progress to expand few capacities in anti-inflammatory therapeutic category. As expected, Export markets are opening up for the formulation division and it will drive the margins for that division.

FOR AARTI DRUGS LIMITED

ADHISH P. PATIL

CHIEF FINANCIAL OFFICER

